Stephan Bodis

ORCID: 0000-0003-1078-8711
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Ultrasound and Hyperthermia Applications
  • Cancer-related Molecular Pathways
  • Advanced Radiotherapy Techniques
  • Effects of Radiation Exposure
  • Advances in Oncology and Radiotherapy
  • Radiation Therapy and Dosimetry
  • Photoacoustic and Ultrasonic Imaging
  • Endometrial and Cervical Cancer Treatments
  • Prostate Cancer Diagnosis and Treatment
  • Prostate Cancer Treatment and Research
  • Head and Neck Cancer Studies
  • Cancer Treatment and Pharmacology
  • Cell death mechanisms and regulation
  • Lung Cancer Treatments and Mutations
  • Cancer Research and Treatments
  • Glioma Diagnosis and Treatment
  • Radiomics and Machine Learning in Medical Imaging
  • Infrared Thermography in Medicine
  • Cervical Cancer and HPV Research
  • Breast Cancer Treatment Studies
  • Bladder and Urothelial Cancer Treatments
  • Thermal Regulation in Medicine
  • DNA Repair Mechanisms
  • PI3K/AKT/mTOR signaling in cancer
  • Ovarian cancer diagnosis and treatment

University of Zurich
2001-2025

Kantonsspital Aarau
2014-2023

University Hospital of Zurich
2014-2023

Foundation for Research on Information Technologies in Society
2021-2022

Klinik und Poliklinik für Strahlentherapie und Radioonkologie
2017

Kantonsspital Graubünden
2015

University of Bern
2015

University Hospital of Bern
2015

International Breast Cancer Study Group
2015

Kantonsspital St. Gallen
2015

The therapeutic responsiveness of genetically defined tumors expressing or devoid the p53 tumor suppressor gene was compared in immunocompromised mice. Tumors contained a high proportion apoptotic cells and typically regressed after treatment with gamma radiation adriamycin. In contrast, p53-deficient treated same regimens continued to enlarge few cells. Acquired mutations were associated both resistance relapse p53-expressing tumors. These results establish that defects apoptosis, here...

10.1126/science.7973635 article EN Science 1994-11-04

PurposeRadiation therapy, a key component of cancer management, is required in more than half new patients, particularly low- and middle-income countries (LMICs). The projected rise incidence over the next decades LMICs will result an increasing demand for radiation therapy services. Considering present that 2020 (as listed GLOBOCAN), we evaluated current anticipated needs infrastructure staffing by each LMICs.Methods MaterialsBased on World Bank classification, 139 fall category LMICs....

10.1016/j.ijrobp.2014.03.002 article EN public-domain International Journal of Radiation Oncology*Biology*Physics 2014-04-18

Hyperthermia has been shown to improve the effectiveness of chemotherapy and radiotherapy in treatment cancer. This paper summarises all recent clinical trials registered ClinicalTrials.gov registry.The records 175,538 at were downloaded on 29 September 2014 a database was established. We searched this for hyperthermia or equivalent words.A total 109 identified which part regimen. Of these, 49 (45%) had hyperthermic intraperitoneal after cytoreductive surgery (HIPEC) as primary intervention,...

10.3109/02656736.2015.1040471 article EN International Journal of Hyperthermia 2015-05-15

Purpose To investigate neoadjuvant chemotherapy with cisplatin and gemcitabine followed by extrapleural pneumonectomy or without radiation therapy in patients potentially resectable malignant pleural mesothelioma (MPM). Patients Methods Eligible had MPM clinical stage T1-3, N0-2, M0 disease considered to be completely a WHO performance status of 0 2. Neoadjuvant consisted three cycles 80 mg/m 2 on day 1 1,000 days 1, 8, 15, given every 28 days. Surgery consist complete pneumonectomy,...

10.1200/jco.2004.10.071 article EN Journal of Clinical Oncology 2004-08-30

Patients with biochemical failure (BF) after radical prostatectomy may benefit from dose-intensified salvage radiation therapy (SRT) of the prostate bed. We performed a randomized phase III trial assessing dose intensification.Patients BF but without evidence macroscopic disease were randomly assigned to either 64 or 70 Gy. Three-dimensional conformal intensity-modulated therapy/rotational techniques used. The primary end point was freedom BF. Secondary points acute toxicity according...

10.1200/jco.2015.63.3529 article EN Journal of Clinical Oncology 2015-11-03

The vascular endothelial growth factor (VEGF) receptor is a major target for anti-angiogenesis-based cancer treatment. Here we report the treatment effect of ionizing radiation in combination with novel orally bioavailable VEGF tyrosine kinase inhibitor PTK787/ZK222584 on cell proliferation vitro and tumour xenografts vivo. Combined human umbilical vein cells increasing doses abrogated VEGF-dependent dose-dependent way, but inhibition was not due to apoptosis induction. In vivo, combined...

10.1054/bjoc.2001.2166 article EN cc-by-nc-sa British Journal of Cancer 2001-12-01

To analyze the impact of weight loss before and during chemoradiation on survival outcomes in patients with locally advanced head neck cancer. From 07/1994-07/2000 a total 224 squamous cell carcinoma were randomized to either hyperfractionated radiation therapy alone or same combined two cycles concomitant cisplatin. The primary endpoint was time any treatment failure (TTF); secondary endpoints locoregional recurrence-free (LRRFS), distant metastasis-free (DMFS) overall (OS). Patient...

10.1186/s13014-014-0319-y article EN cc-by Radiation Oncology 2015-01-16

PURPOSE The patterns of presentation, histologic pattern (nodular or diffuse), treatment, and long-term outcome were studied in patients with lymphocyte-predominant (LP) Hodgkin's disease (HD) to determine whether these should be treated differently than other subtypes HD. PATIENTS AND METHODS Pathology was reviewed for 97 an initial diagnosis LPHD made between 1970 1993. Seventy-five had on review: 55 nodular LPHD, 14 diffuse six LP histology without subclassification. There 60 males (80%)...

10.1200/jco.1997.15.9.3060 article EN Journal of Clinical Oncology 1997-09-01
Coming Soon ...